Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 34-38

  Couec, Marie Laure ^a   André, Nicolas ^b   Thebaud, Estelle ^c   Minckes, Odile ^d   Rialland, Xavier ^e   Corradini, Nadège ^a   Aerts, Isabelle ^f   Bérard, Perrine Marec ^g   Bourdeaut, Franck ^f   Leblond, Pierre ^c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b TIMONE HOSPITAL   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d CHU CÔTE DE NACRE   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f INSTITUT CURIE   (France)

^g Institute d'Hémato Oncologie Pédiatrique   (France)

Author keywords

Bevacizumab; Brain tumors; Children; Glioma

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTROCYTOMA; BLEEDING; BLOOD PRESSURE MEASUREMENT; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; EPENDYMOMA; GLIA; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; MEDICAL RECORD REVIEW; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NEUTROPENIA; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREND STUDY; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES;

EID: 84861203795     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24066     Document Type: Article

References (20)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182- 1186.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669- 676.
3. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008; 8: 309- 316.
4. André N, Verschuur A, Rossler J, et al. Anti-angiogenic therapies for children with cancer. Curr Cancer Drug Targets 2010; 10: 879- 889.
5. Kabbinavar F, Irl C, Zurlo A, et al. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 2008; 75: 215- 223.
6. Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28: 949- 954.
7. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427- 434.
8. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008; 112: 2267- 2273.
9. Desjardins A, Reardon DA, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008; 14: 7068- 7073.
10. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52: 791- 795.
11. Reismüller B, Azizi AA, Peyrl A, et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer 2010; 54: 681- 686.
12. Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008; 19: 807- 813.
13. Parekh C, Jubran R, Erdreich-Epstein A, et al. Treatment of children with recurrent high-grade gliomas with a bevacizumab containing regimen. J Neurooncol 2011; 103: 673- 680.
14. Macdonald DR, Cascino TL, Schold SC, Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277- 1280.
15. Glade Bender JL, Adamson PC, Reid JM, et al. Children's Oncology Group Study. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study. J Clin Oncol 2008; 26: 399- 405.
16. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28: 3069- 3075.
17. Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol 2010; 12: 985- 990.
18. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42: 3127- 3139.
19. Ryan AM, Eppler DB, Hagler KE, et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27: 78- 86.
20. Rozen WM, Joseph S, Lo PA. Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr Neurosurg 2008; 44: 324- 328.